87359-44-2

Basic information

• Product Name: 2-[2-methoxy-4-(methylsulfonyl)phenyl]-3H-imidazo[4,5-c]pyridine hydrochloride (1:1)
• Synonyms: LY 163252
• CAS NO: 87359-44-2
• Molecular Formula: C₁₄H₁₃N₃O₃S*ClH
• Molecular Weight: 339.7973
• Mol File: 87359-44-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 616.1°C at 760 mmHg
• Flash Point: 326.4°C
• Vapor Pressure: 4.15E-15mmHg at 25°C
• CAS DataBase Reference: 2-[2-methoxy-4-(methylsulfonyl)phenyl]-3H-imidazo[4,5-c]pyridine hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-methoxy-4-(methylsulfonyl)phenyl]-3H-imidazo[4,5-c]pyridine hydrochloride (1:1)(87359-44-2)
• EPA Substance Registry System: 2-[2-methoxy-4-(methylsulfonyl)phenyl]-3H-imidazo[4,5-c]pyridine hydrochloride (1:1)(87359-44-2)

Safety Data

• Hazardous Substances Data: 87359-44-2(Hazardous Substances Data)

Usage

Structure

Consists of a 3H-imidazo[4,5-c]pyridine ring system

Functional Groups

Methoxy group (CH3O) at position 2 of the phenyl ring
Methylsulfonyl group (CH3SO2) at position 4 of the phenyl ring
Hydrochloride salt (HCl) in a 1:1 ratio

Usage

Pharmaceutical research
Drug development

Pharmacological Properties

Under investigation
Not fully elucidated

Potential Applications

Study of potential treatments for various diseases and conditions

Pharmacological and Toxicological Investigation

Ongoing research for therapeutic applications

Upstream product

• 79128-27-1 2-methoxy-4-methylthiobenzoic acid methyl ester 
• 72856-73-6 2-methoxy-4-(methylsulfanyl)benzoic acid 
• 54-96-6 3,4-diaminopyridine 
• 86315-69-7 2-<2-methoxy-4-(methylsulfenyl)phenyl>imidazo<4,5-c>pyridine hydrochloride 

Relevant articles and documents

Structure-activity relationships of arylimidazopyridine cardiotonics: Discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine

Recently several noncatecholamine, nonglycoside cardiotonic drugs have been discovered that possess both inotropic and vasodilator activities in experimental animals and man. Prototypical compounds include amrinone, sulmazole, and fenoximone. We investigated the structural requirements necessary for optimal inotropic activity in a series of molecules containing a heterocyclic ring fused to 2-phenylimidazole and discovered that 2-phenylimidazo[4,5-c]pyridines were generally 5-10-fold more potent than analogous 2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H- imidazo[4,5-c]pyridine hydrochloride). The structure-activity relationship of this series is presented and compared to that of the imidazo[4,5-b]pyridine and purine series.